Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
August 27, 2024 07:00 AM Eastern Daylight Time SCOTCH PLAINS, N.J.–(BUSINESS WIRE)–Navigator Medicines, Inc., a privately-held biotech company leading the advancement of biologics for targeted immune regulation and restoration, today announced a Series A financing…